Trevi Therapeutics, Inc. (TRVI:NASDAQ) closed at $13.65 on November 13, 2026, up 0.22% on the day. The stock trades 32.5% below its 52-week high of $20.22 and 39.0% above its 52-week low of $9.82. Over the past year, it gained 20.1%. Trevi Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, TRVI closed higher on 121 days (48%). Its best day was November 26, 2025 (+16.99%) and its worst was July 20, 2026 (-12.06%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Find more stocks like TRVI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.